UniQure Advances AMT-191 Trial in Fabry Disease

2 hours ago 1

 uniQure N.V. (NASDAQ: NASDAQ:QURE), a gene therapy company with a market capitalization of $767 million, announced today the completion of enrollment for the first cohort in a Phase I/IIa trial of AMT-191, an investigational treatment for Fabry disease. Following a safety assessment by the Independent (LON:IOG) Data Monitoring Committee (IDMC), which found no significant safety concerns, the company has been advised to proceed with dosing the second cohort.

https://www.investing.com/news/company-news/uniqure-advances-gene-therapy-trial-for-fabry-disease-93CH-3845103

Read Entire Article